Embedded Files
The research project "Can we trust health economic evaluations of new pharmaceuticals? Examining the impact of the researcher's degrees of freedom using a many-analysts approach" will run between 2024-2026 and is funded by the Swedish Research Council for Health, Working Life and Welfare (Forte).
Given the large economic and public health consequences of drug reimbursement decisions based on cost-effectiveness evidence, it is essential that the cost-effectiveness evidence provides valid input to decision-makers. Our long-term goal is to develop a framework and guidelines for improving reproducibility and reducing the impact of researcher degrees of freedom in pharmacoeconomic models. The primary aims of the project are (1) to determine to what degree published pharmacoeconomic models of new cancer drugs are reproducible, and (2) to investigate the impact of researchers’ degrees of freedom in the pharmacoeconomic modeling of two novel cancer drugs.
The Research Team
Page updated
Google Sites
Report abuse